Last reviewed · How we verify
Rabeprazole Sodium 20mg
Rabeprazole Sodium 20mg, marketed by Zeria Pharmaceutical, is a proton pump inhibitor with a well-established presence in the gastrointestinal therapeutic area. The drug's key strength lies in its strong patent protection, with the key composition patent expiring in 2028, providing a significant barrier to generic competition. The primary risk is the eventual loss of exclusivity in 2028, which could lead to a decline in revenue due to increased competition from generics.
At a glance
| Generic name | Rabeprazole Sodium 20mg |
|---|---|
| Also known as | Pariet, Reference drug, Zifam Pinnacle, Mumbai, India |
| Sponsor | Zeria Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (PHASE4)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PHASE4)
- Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (PHASE1)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (PHASE4)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabeprazole Sodium 20mg CI brief — competitive landscape report
- Rabeprazole Sodium 20mg updates RSS · CI watch RSS
- Zeria Pharmaceutical portfolio CI